Vergoeding 2017-2021 voor ATC-subgroep C09CA : Angiotensine-ii-antagonisten
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| C09CA01 Losartan (Cozaar ®) | 2.564.900 | 3.059.100 | 5.498.300 | 5.677.800 | 4.905.100 |
| C09CA02 Eprosartan (Teveten ®) | 378.180 | 363.030 | 113.450 | 48.291 | 52.312 |
| C09CA03 Valsartan (Diovan ®) | 3.226.000 | 3.565.200 | 2.702.600 | 2.551.800 | 2.970.600 |
| C09CA04 Irbesartan (Aprovel ®) | 2.529.500 | 2.643.100 | 4.278.100 | 4.182.000 | 3.744.600 |
| C09CA06 Candesartan (Atacand ®) | 1.086.200 | 1.209.900 | 1.777.100 | 2.006.600 | 2.004.300 |
| C09CA07 Telmisartan (Micardis ®) | 798.050 | 776.110 | 1.284.300 | 1.440.600 | 1.224.600 |
| C09CA08 Olmesartan (Olmetec ®) | 1.849.000 | 692.860 | 582.140 | 825.340 | 651.380 |
| Totaal | 12.431.830 | 12.309.300 | 16.235.990 | 16.732.431 | 15.552.892 |